ScreenerHero

OKUROnKure Therapeutics Inc. Class A Common Stock

NAS · US · Healthcare · Biotechnology · onkuretherapeutics.com
3.940USD-3.43%Mkt Cap: 159.16M $P/E: —

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead pr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap159.16M $
Enterprise Value-16.31M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.52M $
Revenue/Share—
Last Price3.940 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees45
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.57
PEG—
EV/EBITDA0.26
EV/Revenue—
P/S—
P/B0.92
EPS (TTM)-2.91
EPS (Forward)-1.53
52W Range
2.23054% of range5.380
52W High5.380 USD
52W Low2.230 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-105.93%
ROA-95.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.83M $
CapEx (TTM)46.00K $
FCF Margin—
FCF Yield-17.03%
Net Debt-175.46M $
Net Debt/EBITDA2.84
Balance Sheet
Debt/Equity0.01
Current Ratio26.75
Quick Ratio26.55
Book Value/Sh4.250 USD
Cash/Share4.356 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateOct 7, 2024
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.50 USD
Upside (mean)+293.4%
Target Range11.00 USD – 21.00 USD
$11.00+293.4% to mean$21.00
# Analysts4
Ownership
Shares Out.40.40M
Float21.36M
Insiders10.45%
Institutions87.22%
Short Interest
Short Ratio7.2d
Short % Float3.26%
Short % Out.2.93%
Shares Short1.19M
Short (prev mo.)878.67K
Technical
SMA 504.206 (-6.3%)
SMA 2003.630 (+8.5%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)128.27K
Avg Vol (10d)128.42K
Technical Indicators
RSI (14)43.6
MACD-0.0501
MACD Signal-0.0528
MACD Hist.+0.0026
BB Upper4.244 USD
BB Middle4.039 USD
BB Lower3.834 USD
BB Width10.14%
ATR (14)0.2969 USD
Vol Ratio (20d)0.44x